Patients were aged 18 years or older, had stage IIIb or stage IV ALK-positive NSCLC that had progressed while they were on crizotinib therapy....ALK fusion was detected at baseline in 75 (51%) of the 147 patients with assessable responses (table 4). 70 (93%) had an EML4–ALK fusion; variant 1 was the most frequent (table 4)....20 (44%) of 45 patients with secondary ALK alterations, 43 (57%) of 75 with detectable ALK fusion, and 56 (57%) of 98 without detectable resistance mechanisms had an objective response to ensartinib....The proportion of patients with objective responses to ensartinib was similar among patients with the EML4–ALK fusions (table 4)